No abstract available.
Glioma*

No abstract available.
Glioma*

No abstract available.
Glioma*

No abstract available.
Glioma*

Objective To investigate the expression and significance of the CYB561D2 gene in the prognostic evaluation of patients with glioma based on bioinformatics analysis. Methods A total of 78 pathological specimens were collected from the patients with glioma who received surgical treatment in Department of Neurosurgery，Anqing Municipal Hospital，from October 2018 to December 2022 and were enrolled as experimental group，and 32 specimens of normal brain tissue that must be removed during the surgical pathway were enrolled as control group. Quantitative real-time PCR and immunohistochemistry were used to measure the mRNA and protein expression levels of the CYB561D2 gene in both groups. Results The CYB561D2 gene was highly expressed in the glioma tissue of the patients in the experimental group，and the pathological grade of the tumor increased with the increase in the expression of the CYB561D2 gene，while there were no significant mRNA and protein expression levels of the CYB561D2 gene in the control group，with significant differences between the two groups（χ2=2.75 and 2.19，P<0.05）. Conclusion There are significant increases in the mRNA and protein expression levels of the CYB561D2 gene in glioma，suggesting that CYB561D2 is associated with the development，progression，and malignancy of glioma.
Glioma

No abstract available.
Brain Stem* ; Glioma*

No abstract available.
Encephalitis* ; Glioma* ; Humans

To assess the degree of malignancy in cerebral gliomas at the time of diagnosis, we compared the metabolic ratio using 18F-fluorodeoxyglucose(FDG)-Positron Emission Tomography(PET) with histologic grading and proliferative index(Ki-67) of cerebral gliomas. Materials for this study were histologically-examined 21 gliomas and they were divided into glioblastomas as group 1, anaplastic gliomas as group 2, and low-grade gliomas as group 3. The visual analysis of FDG-PET images showed hypermetabolic lesions in 14(87.5%) out of 16 high-grade gliomas (glioblastomas and anaplastic gliomas), and hypometabolic lesions in 4(80%) out of 5 low-grade gliomas. Tumor to cerebellum ratio(T/Cbll) in FDG-PET was used as metabolic ratio and the values of T/Cbll in each group were 1.30+/-0.10, 0.73+/-0.07, 0.70+/-0.07, respectively. In comparision of T/Cbll between group 1 with remaining two groups, differences were statistically significant(p=0.0002, p=0.0002, respectively), however, there was no statistical difference between group 2 and group 3. The values of Ki-67 were 24.16+/-5.66 in group 1, 8.10+/-2.70 in group 2, 5.46+/-1.23 in group 3, and differences were statistically significant between group 1 and group 2, 3(p=0.015, p=0.015, respectively), but there was no statistical difference between group 2 and group 3. The correlation between T/Cbll and Ki-67 was good and statistically significant(p=0.0047). In conclusion, the visual and semiquantitative analysis of FDG-PET would be helpful in determining the degree of malignancy in cerebral gliomas.
Cerebellum ; Diagnosis ; Glioblastoma ; Glioma*

Chordoid glioma, a recently introduced clinicopathologic entity, is a rare neoplasm occurring mainly in the third ventricle and hypothalamus. The authors had experienced a case of chordoid glioma combined with Rathke's cleft cyst which occurred in the sellar and suparasellar region. Here we report clinical, radiological, and histopathological features of this neoplasm with review of literature
Glioma* ; Hypothalamus ; Third Ventricle

No abstract available.
Cell Line* ; Glioma*